Surgery Partners, Inc. filed its quarterly report on Form 10-Q with the SEC on August 10, 2026, covering the three- and six-month periods ended June 30, 2026.

Key Highlights

  • Q2 2026 revenues: $848.9 million, compared to $826.2 million in Q2 2025, according to the filing.
  • Six-month revenues: $1,659.8 million for the first half of 2026, up from $1,602.2 million in the same period of 2025.
  • Net loss attributable to Surgery Partners, Inc.: $(15.0) million for Q2 2026 and $(50.9) million for the six months ended June 30, 2026.
  • Basic and diluted loss per share: $(0.12) for Q2 2026 and $(0.40) for the six-month period, the company reported.
  • Total assets: $8,049.7 million as of June 30, 2026, compared to $8,119.7 million at December 31, 2025.
  • Long-term debt: $3,648.3 million (less current maturities) as of June 30, 2026, per the filing.
  • Shares outstanding: 130,918,260 shares of common stock as of August 3, 2026.

Surgery Partners Q2 2026: Revenue Growth Alongside Net Loss for Parent Shareholders

Surgery Partners, Inc. (Nasdaq: SGRY), a Brentwood, Tennessee-based operator of surgical facilities, reported second-quarter 2026 revenues of $848.9 million, up from $826.2 million in the same quarter a year earlier, according to the filing. For the six months ended June 30, 2026, revenues totaled $1,659.8 million versus $1,602.2 million in the prior-year period. Cost of revenues for the second quarter was $658.7 million, compared to $630.6 million in Q2 2025, with salaries and benefits representing the largest component at $253.1 million.

The company disclosed operating income of $102.1 million for Q2 2026, down from $111.7 million in Q2 2025. Net interest expense of $69.8 million in the quarter reduced income before taxes to $32.3 million. After accounting for income tax expense of $2.6 million and net income attributable to non-controlling interests of $44.7 million, the net loss attributable to Surgery Partners, Inc. was $(15.0) million for Q2 2026, compared to a net loss of $(2.5) million in Q2 2025. Transaction and integration costs were $18.4 million in the second quarter.

On the balance sheet, the filing reported total assets of $8,049.7 million as of June 30, 2026. Goodwill and other intangible assets, net, accounted for $5,242.1 million of that figure. Total long-term debt, including current maturities, stood at $3,751.2 million. The retained deficit widened to $(866.1) million from $(815.2) million at December 31, 2025. Cash and cash equivalents were $216.7 million, compared to $239.9 million at year-end 2025. As of June 30, 2026, common shares issued and outstanding were 130,886,397.

What Was Disclosed

Surgery Partners filed its Form 10-Q for the quarter ended June 30, 2026, disclosing revenue growth in both the second quarter and first half of the year, an operating loss attributable to the parent company, updated balance sheet figures, and share count information as of August 3, 2026.